Tea Vaccine Research Institute (261780) has 1 disclosed insider purchases and 1 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩75M ($52K) in reported transaction value. The earliest filing StockDrifts holds for Tea Vaccine Research Institute is dated 2024-03-29; the most recent is 2026-04-30. Across these filings the average return since disclosure is +9.49%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | SELL | 장외매도 | 차바이오텍 CHA Biotech | - | -8.9M | ₩4,100 | -8.9% | ₩36.7B ($25.5M) |
| 2026-03-26 | SELL | Market Sell | 고정재 fixing material | Internal director | -14.3K | ₩4,530 | +22.1% | ₩65M ($45K) |
| 2025-09-25 | BUY | Market Buy | HAN SEUNGIL | CEO | 3.7K | ₩2,735 | -3.1% | ₩10M ($7K) |
| 2025-04-01 | BUY | 주식매수선택권 | 고정재 fixing material | Internal director | 26.7K | ₩2,830 | -6.4% | ₩75M ($52K) |
| 2024-03-29 | BUY | 주식매수선택권 | 조정기 regulator | president | 50.0K | ₩5,140 | -48.4% | ₩257M ($178K) |
| 2024-03-29 | BUY | 주식매수선택권 | 고정재 fixing material | Internal director | 26.7K | ₩5,140 | -48.4% | ₩137M ($95K) |
Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.